1. Home
  2. CNM vs UTHR Comparison

CNM vs UTHR Comparison

Compare CNM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$50.26

Market Cap

9.0B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
UTHR
Founded
1996
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Durable Goods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
20.3B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
CNM
UTHR
Price
$50.26
$488.92
Analyst Decision
Buy
Buy
Analyst Count
11
12
Target Price
$60.00
$495.08
AVG Volume (30 Days)
2.5M
424.3K
Earning Date
12-09-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
7.24
16.08
EPS
2.25
26.38
Revenue
$7,740,000,000.00
$3,128,400,000.00
Revenue This Year
$4.45
$13.64
Revenue Next Year
$4.43
$5.78
P/E Ratio
$22.35
$18.55
Revenue Growth
11.02
13.50
52 Week Low
$43.18
$266.98
52 Week High
$67.18
$492.62

Technical Indicators

Market Signals
Indicator
CNM
UTHR
Relative Strength Index (RSI) 55.83 68.10
Support Level $44.59 $470.13
Resistance Level $50.10 $492.62
Average True Range (ATR) 1.61 10.72
MACD 0.65 -0.53
Stochastic Oscillator 93.62 89.55

Price Performance

Historical Comparison
CNM
UTHR

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: